April 30, 2026Journal of the American College of Cardiology
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention
Why the study?
Individual variability in clopidogrel response might influence PCI results, prompting evaluation of whether point-of-care platelet inhibition measurements correlate with clinical outcomes.
Does high pre-procedural platelet reactivity measured by a point-of-care assay predict 30-day major adverse cardiac events in patients undergoing PCI on clopidogrel?
Population
160 patients receiving clopidogrel before PCI
Comparison
Quartiles of P2Y12 reaction units measured by VerifyNow P2Y12 assay
Design
Prospective cohort study
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports platelet reactivity testing to stratify ischemic risk after PCI; leaves open whether guided antiplatelet adjustment improves outcomes.**[[1]](https://www.jacc.org/doi/abs/10.1016/j.jacc.2008.06.038)[[2]](https://www.sciencedirect.
Structured PICO
Does high pre-procedural platelet reactivity measured by a point-of-care assay predict 30-day major adverse cardiac events in patients undergoing PCI on clopidogrel?
P
Population
160 patients receiving clopidogrel before undergoing percutaneous coronary intervention (PCI)
I
Intervention
Point-of-care measurement of platelet reactivity by VerifyNow P2Y12 assay (specifically assessing high P2Y12 reaction units [PRU] in the fourth quartile)
C
Comparator
Lowest quartile of P2Y12 reaction units (PRU)
O
Outcome
30-day occurrence of major adverse cardiac events (MACE)composite
High pre-procedural platelet reactivity measured by a point-of-care assay in patients on clopidogrel predicts 30-day MACE following PCI, primarily driven by periprocedural myocardial infarction.
Cite This Study
Patti et al. (2008) studied this question.